Hyperuricemia, gout and obesity: should weight management be more of a focus in gout management?

Authors

Sabrina Scilletta, Maurizio Di Marco, Giosiana Bosco, Francesco Di Giacomo Barbagallo, Francesco Galeano, Andrea Tumminia, Agostino Milluzzo, Agostino Gaudio, Lucia Frittitta, Roberto Scicali, Pietro Castellino, Salvatore Piro, Naveed Sattar, Antonino Di Pino

Published in

Nutrition, metabolism, and cardiovascular diseases : NMCD. Pages 104860. Jul 09, 2026. Epub Jul 09, 2026.

Abstract

Hyperuricemia-elevated serum uric acid (SUA)-is the pathogenic driver of gout and is recognized as a systemic condition associated with cardiometabolic risk, including cardiovascular disease and type 2 diabetes, although causality remains debated. Its global prevalence has risen substantially over decades, paralleling the growing epidemic of obesity and increasing life expectancy. This narrative review examines the relationship between adiposity and hyperuricemia and summarises the knowledge about the impact of weight-loss interventions on SUA levels and gout risk.
Epidemiological evidence supports a bidirectional relationship between adiposity and hyperuricemia, although Mendelian randomisation studies suggest that excess adiposity is likely a cause rather than consequence of elevated SUA. Multiple mechanisms may underlie this association, including insulin resistance, reduced renal urate excretion, visceral adiposity, and dietary factors. Weight reduction is now recommended as a cornerstone of hyperuricemia and gout management in individuals with overweight or obesity. Lifestyle and dietary interventions are associated with modest reductions in SUA and gout risk. Bariatric surgery achieves substantial and sustained weight loss, leading to significant long-term reductions of SUA and gout incidence, despite a transient postoperative SUA increase. Recently, pharmacological weight-loss therapies (i.e. glucagon-like peptide-1 receptor agonists and tirzepatide) demonstrated meaningful reductions in SUA levels, potentially largely mediated by weight loss.
Integrating obesity management into hyperuricemia care represents a key strategy to reduce gout incidence and flares. Further research evaluating emerging anti-obesity therapies impact on hyperuricemia-specific outcomes would be useful, perhaps particularly in people experiencing ongoing flares despite other therapies and with obesity.

PMID:
42469142
Bibliographic data and abstract were imported from PubMed on 18 Jul 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.